Top Story Today
UCB Drops $1.15 Billion on a Brain Cell Transplant for Epilepsy
A 92% median reduction in disabling seizures. That's the early-stage number that convinced UCB to pay up to $1.15 billion for Neurona Therapeutics and its experimental cell therapy, NRTX-1001. The treatment transplants lab-grown inhibitory neurons directly into the brains of patients whose epilepsy doesn't respond to drugs (roughly one in three). UCB is putting $650 million down in cash, with $500 million more tied to clinical and commercial milestones. The real test: a Phase 3 sham-controlled trial set to begin dosing in the second half of 2025.
Why it matters: This deal marks one of the largest bets on regenerative medicine for the brain, signaling that Big Pharma sees cell therapy as a viable path beyond traditional pills for neurological disorders. For 15 million people living with drug-resistant epilepsy worldwide, it could represent a fundamentally new category of treatment.
Read more →AI and Drug Discovery
OpenAI Built an AI That Speaks Fluent Biology
OpenAI launched GPT-Rosalind, a purpose-built AI model for drug discovery that ranked above the 95th percentile of human experts at predicting RNA sequence function in third-party testing. Amgen, Moderna, and Novo Nordisk are early adopters through a restricted-access program. The model synthesizes scientific literature, generates hypotheses, and connects to 50-plus research tools. It's OpenAI's clearest signal yet that it wants biology to be its next frontier.
Read more →AI Chip Maker Cerebras Files for IPO
Cerebras Systems, whose wafer-scale processors ran molecular dynamics simulations 180 times faster than the world's top supercomputer, filed its S-1 on Nasdaq. Backed by a $10 billion OpenAI contract and 245% revenue growth, the company offers biotech a radically different approach to the computational bottleneck in drug discovery.
Read more →Oncology Watch
Merck Unveils Its Secret Weapon for Life After Keytruda
With Keytruda's $29.5 billion in 2024 annual sales facing a 2028 patent cliff, Merck debuted early data on MK-2010, a bispecific antibody that blocks both PD-1 and VEGF simultaneously. Merck hasn't announced Phase 3 plans yet, putting it behind rivals like Akeso's ivonescimab.
Read more →A Cancer Drug Designed to Ignore Everything Except the Tumor
Janux Therapeutics dosed its first patient with JANX014, a "double-masked" T cell engager for prostate cancer. The drug's binding arms are covered by molecular caps that only get removed by enzymes concentrated inside tumors, dramatically reducing off-target immune binding in preclinical models. If the approach works in humans, it could rewrite the safety playbook for an entire drug class.
Read more →Industry and Policy
Roivant's CEO Says the Biotech Industry Is Worried About the Wrong Thing
Roivant CEO Matt Gline called the industry's China obsession a "red herring" on a major podcast, pointing to AI hype and talent shortages as the real threats. It's a bold stance given that Chinese labs now originate roughly a third of global early-stage pipeline compounds, and the BIOSECURE Act is pushing American biotechs to rewire their supply chains.
Read more →